Chronic Low-Grade Systemic Inflammatory State and Insulin Resistance: Implications for Metabolic Health


Authors : Dr. Luis Gomez Pena

Volume/Issue : Volume 9 - 2024, Issue 12 - December

Google Scholar : https://tinyurl.com/5n6x6tzx

Scribd : https://tinyurl.com/3yuapy59

DOI : https://doi.org/10.5281/zenodo.14550849

Abstract : Insulin resistance, recognized since 1936 as part of non-communicable diseases, has been an evolving topic. This work updates the scientific community on this epiphenomenon as a component of a low-grade systemic inflammatory state. Through searches in PubMed, Redalyc and Google Scholar, 368 articles were identified, 49 references were selected, of which 77.5% were published between 2020 and 2024. The historical periodization includes the initial differentiation of insulin- sensitive and insulin-insensitive diabetic patients in 1936, which laid the foundations for its study. Between 1979 and 1987, the development of the euglycemic-hyperinsulinemic clamp marked an advance in its quantification; from 1988 to 1999, its role in metabolic syndrome was consolidated, and since 2000, research has highlighted the influence of the intestinal microbiota on insulin resistance and its link to inflammation.

Keywords : Insulin Resistance, Low-Grade Systemic Inflammatory State, Metabolic Syndrome.

References :

  1. Meza Peñafiel A, Gómez Pedraza A, Martínez Leo EE. Metabolic syndrome, intestinal microbiota and probiotics. In: Nutrition in an era of sustainable development. Editorial Académica Española; 2021. Chapter 2, p. 30-36. https://www.researchgate.net/profile/Edwin-Martinez-Leo/publication/354921289_Nutricion_en_una_era_de_desarrollo_sostenible/links/61710e51c10b387664c8848f/Nutricion-en-una-era-de-desarrollo-sostenible.pdf#page=27
  2. Espinosa Brito AD. Health, complexity and non-communicable diseases. Rev Finlay. 2023;13(2). ISSN: 2221-2434.
  3. Santos Lozano E. Insulin resistance: literature review. Rev Méd Hondur. 2022;90(1):1-94. https://doi.org/10.5377/rmh.v90i1.13824.
  4. Castro Quintanilla DA, Rivera Sandoval N, Solera Vega A. Metabolic syndrome: generalities and early approach to avoid cardiovascular risk and type 2 diabetes mellitus. Rev Méd Sinergia. 2023;8(2):e960. doi: https://doi.org/10.31434/rms.v8i2.960
  5. Li M, Chi X, Wang Y, Setrerrahmane S, Xie W, Xu H. Trends in insulin resistance: insights into mechanisms and therapeutic strategy. Signal Transduction and Targeted Therapy. 2022;7(216). Available at: https://doi.org/10.1038/s41392-022-01073-0
  6. Gutiérrez Gómez M. Chronic low-grade inflammation in obesity: biomarkers and clinical perspectives. Final Degree Project. Santander; June 2024. https://repositorio.unican.es/xmlui/handle/10902/33581.
  7. Kahn CR, Baird KL, Jarrett DB, Flier JS. Direct demonstration that receptor cross-linking or aggregation is important in insulin action. Proc Natl Acad Sci USA . 1978;75(9):4209-13.
  8. Narváez Ramos MdC, Silvestre Ramos R, Ortega Castillo HF. Insulin resistance in overweight and obese adults. Rev Eugenio Espejo. 2024;18(2):May-August.
  9. De Fronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol Endocrinol Metab. 1979;237(3): 214-23. doi: 10.1152/ajpendo.1979.237.3.E214.
  10. Matthews DR, Hosker JR, Rudensky AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment of insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in humans. Diabetologia. 1985;28(7):412-9. doi: 10.1007/BF00280883.
  11. Varela-Vega Y, Roy-García IA, Pérez-Rodríguez M, Velázquez-López L. Diagnostic certainty of the FINDRISC instrument to identify insulin resistance in adults. Rev Med Inst Mex Seguro Soc. 2023;61(1):33–41. Available: http://revistamedica.imss.gob.mx/.
  12. Narváez Ramos MC, Silvestre Ramos R, Ortega Castillo HF. Insulin resistance in overweight and obese adults. Rev Eugenio Espejo. 2024;18(2):[no pages]. ISSN: 1390-7581; ISSN-E: 2661-6742.
  13. Vega-Cárdenas M, Flores-Sánchez J, Torres-Rodríguez ML, Sánchez-Armáss O, Vargas Morales JM, et al. Distribution of the triglyceride-glucose (TyG) index and the homeostatic model for the assessment of insulin resistance in late adolescence in Mexicans. Nutr Hosp. 2022;39(6):1349-1356. doi: 10.20960/nh.04120.
  14. Yanes Quesada M, Cruz Hernández J, Cabrera Rode E, González Hernández O, Calderin Bouza R, Yanes Quesada MA. Glucose-triglyceride ratio as a marker of insulin resistance in patients diagnosed with essential arterial hypertension. Cuban Journal of Medicine. 2020;59(1):1327.
  15. Reaven GM. Banting Lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37(12):1595-607. doi: 10.2337/diab.37.12.1595.
  16. Milian EJ, Anzules JB, Betancourt-Castellanos L, Izaguirre-Bordelois M, Caballero AE. Metabolic syndrome and its relationship with the intestinal microbiota. Repert Med Cir. 2024;33(1):14-20. DOI: 10.31260/RepertMedCir.01217372.1354
  17. Hotamisligil GS, Spiegelman BM. Tumor necrosis factor alpha: a key component of the obesity-diabetes link. Diabetes. 1994;43(11):1271–8. doi:10.2337/diab.43.11.1271
  18. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999;257(1):79–83. doi:10.1006/bbrc.1999.0255
  19. Villasis-Keever MA, Zurita-Cruz JN, Nava-Sanchez KD, Barradas-Vázquez AS, López-Beltran AL, Espíritu-Díaz ME, et al. Liver enzyme levels in adolescents with obesity and insulin resistance: a propensity score matching analysis. Bol Med Hosp Infant Mex. 2024;81(4). doi:10.24875/BMHIM.23000161.
  20. Gutiérrez Rodelo C, Roura Guiberna A, Olivares Reyes JA. Molecular mechanisms of insulin resistance: an update. Gac Med Mex. 2017;153(2):214–28.
  21. Cruz Campos FJ, Delgado Jacobo DP. Basic concepts of obesity and overweight. Psic-Obesidad. 2023;13(50). https://doi.org/10.22201/fesz.20075502e.2023.13.50.88412.
  22. Cruz Hidalgo P, Morales Carrasco C, Valle Córdova M, Urdiales Arcos V, Quinteros Romero C, Vázquez Verdugo M, et al. Obesity and cardiovascular disease: from the molecular to the clinical. Cardiometabolic syndrome and chronic degenerative diseases. 2021;XI(1). http://doi.org/10.5281/zenodo.6437779.
  23. González-Domínguez E. Inflammation: from a cellular and molecular perspective. Rarió Gendaruyubi. 2022;5(15):62-62.
  24. Gaytan-Rivera JF, Guerrero-Albac R, Ochoa-Cortes F, Barajas-Espinoza A. Detrimental effects of low-grade inflammation caused by obesity. Ciencia Huasteca Scientific Bulletin of the Higher School of Huejutla. 2022;10(20):1-8.
  25. Ibarra Camacho FD, Murillo Ramos RS, Villalobos Quinchuela LM, Arteaga Morocho EA, Hernández Quimbiulco CI, Tapia Acosta EC, et al. Chronic low-grade inflammation and cardiovascular risk. Rev Latinoam Hipertens. 2022;17(3):235-239. http://doi.org/10.5281/zenodo.6983506.
  26. León-Pedroza JI, González-Tapia LA, del Olmo-Gil E, Castellanos-Rodríguez D, Escobedo G, González-Chávez A. Low-grade systemic inflammation and development of metabolic diseases: from molecular evidence to clinical practice. Surgery and Surgeons. 2015;83(6):543-551.
  27. Rohm TV, Fuchs R, Müller RL, Keller L, Baumann Z, Bosch AJT, Schneider R, Labes D, Langer I, Pilz JB, Niess JH, Delko T, Hruz P, Cavelti-Weder C. Obesity in humans is characterized by intestinal inflammation, as shown by the accumulation of proinflammatory intestinal macrophages. Front Immunol. 2021;12:668654. https://doi.org/10.3389/fimmu.2021.668654.
  28. Hu B, Yang XR, Xu Y, Sun YF, Sun C, Guo W, et al. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. Clin Cancer Res. 2014;20(23):6212–22. doi:10.1158/1078-0432.CCR-14-0442.
  29. Zhang Z, et al. Association between systemic immune inflammation index and obesity among adults: perspectives from NHANES 2017–2018. PLoS One. 2024;19(1):e0308288. doi:10.1371/journal.pone. 0308288.
  30. Ibarra-Sánchez A, Soto-Félix C, Carrasco-Padilla YV, Durán-Pérez SA, Cano-Barraza L, Barraza-Sámano D. Comparative evaluation of the HOMA-IR and HOMA-IR CP indices in the detection of resistance to insulin and its relationship with the lipid profile. Ciencia Latina Rev Cient Multidiscip. 2024;8(5). https://doi.org/10.37811/cl_rcm.v8i5.13923.
  31. Sánchez Reyes PA, Seniscal Arredondo DA, Taracena Pacheco S, Ramírez Fuentes AK, Villanueva Jiménez V, Benítez Benítez LF, et al. Ultrasensitive C-reactive protein as a proinflammatory marker and its association with obesity. ActA Med GA. 2023;21(1):46-50. https://dx.doi.org/10.35366/10902.
  32. Amali Zavaleta Muñiz S, Maravilla Dominguez MA, Martinez Sandoval A, Muñoz Yáñez C, Oliva Guangorena Gómez J. Cardiovascular risk, adiposity and atherogenic and inflammatory markers in patients with metabolic disease. Rev CISA. 2023;5(5):Jul-Dec. https://doi.org/10.58299/cisa.v5i5.41
  33. Bailey CJ, Turner SL. Metformin. N Engl J Med 1996;334(9):574–9. doi:10.1056/NEJM199602293340907
  34. Salazar-Torres ZK. Intestinal dysbiosis, obesity and type 2 diabetes. A scoping review. J Sci. 2024;8(2):3649-3676. https://doi.org/10.56048/MQR20225.8.2.2024.3649-3676.
  35. Machado M, Mora G, Peña S. Involvement of intestinal dysbiosis in obesity. MQR Investigar. 2023;7(2):1215-1240. https://doi.org/10.56048/MQR20225.7.2.2023.1215-1240.
  36. Chan López RE. Intestinal dysbiosis and its relationship with chronic diseases. Rev Investig Proyección Científica. 2024.
  37. Di Renzo L, Gualtieri P, Frank G, Cianci R, Caldarelli M, Leggeri G, et al. Exploring the exposomic spectrum: uncovering endogenous and exogenous factors in chronic non-communicable diseases. Diseases. 2024;12(8):176. doi:10.3390/diseases12080176
  38. Reyes-Díaz RA, Cruz Lara NM. Role of the intestinal microbiota in the development of metabolic syndrome: narrative review. Rev Nutr Clín Metab. 2024;7(1):45-54. DOI: https://doi.org/10.35454/rncm.v7n1.551 .
  39. Vazquez Jimenez JG, Roura Guiberna A, Reyna Jimenez Mena L, Olivares Reyes JA. The role of free fatty acids in insulin resistance. Gac Med Mex. 2017;153:852–63. doi:// dx.doi.org/10.24875/GMM.17002714.
  40. Ortega Catarino MA. Biological characteristics and multidisciplinary treatment of obesity. Psic-Obesidad. 2021;11(41):1-3.
  41. Álvarez Vega M, Cortés Badilla MV, Quirós Mora LM. The impact of the microbiota on cardiovascular disease. Rev Med Sinergia. 2021;6(2):e643. https://doi.org/10.31434/rms.v6i2.643.
  42. Scheithauer TPM, Rampanelli E, Nieuwdorp M, Vallance BA, Verchere CB, van Raalte DH, Herrema H. The gut microbiome as a trigger of metabolic inflammation in obesity and type 2 diabetes. Front Immunol. 2020;11:571731. doi: 10.3389/fimmu.2020.571731.
  43. Herguedas AJU. Digestive leukocytosis in the light of current knowledge. Med Naturista. 2023;17(1):1-3. Spain. https://dialnet.unirioja.es/servlet/articulo?codigo=8787332.
  44. Acevedo Mariles K, Delgado Jacobo DP. Obesity: an overview of its associated factors. Psic-Obesidad. 2021;11(41):1-3.
  45. Janczy A, Aleksandrowicz-Wrona E, Kochan Z, Małgorzewicz S. Impact of diet and synbiotics on selected gut bacteria and intestinal permeability in individuals with excess body weight: a prospective randomized study. Acta Biochim Pol. 2020. https://doi.org/10.18388/abp.2020_5443.
  46. Sagastume Calderon JM, Tejada Carrillo CR, Garcia Herrera SN, Ramirez Chenal PC, Cruz Arana JV, Fernandez Garcia VN. Integrative Medicine in the treatment of metabolic syndrome. Galileo University Forum, Guatemala; 2023. https://biblioteca.galileo.edu/xmlui/bitstream/handle/123456789/1648/Galileo%20(2023)%20Foro%20S%C3%ADndrome%20Metab%C3%B3lico.pdf?sequence=1 .
  47. Ceballos Marcillo AJ, Analuisa Sisalema AY, López Ríos EE, Guaman FA. Benefits of lauric acid to eliminate the fungus *Candida albicans* from the body. Multidisciplinary Scientific-Academic Journal. 2024;9(9). Available at: https://polodelconocimiento.com/ojs/index.php/

48. Argotti Zumbana CF, Villagrán Sánchez MT, Argotti Zumbana RD, Robayo Poveda DM, Ayuquina Lagua MM, Ramírez Fernández DK, et al. Impact of the intestinal microbiota on metabolic control and progression of diabetes mellitus: a challenge to health sustainability in the 21st century. Ibero-American Journal of Education & Society Research. 2024;4(S):[no pages]. DOI: https://doi.org/10.56183/iberoeds.v4iS.688

Insulin resistance, recognized since 1936 as part of non-communicable diseases, has been an evolving topic. This work updates the scientific community on this epiphenomenon as a component of a low-grade systemic inflammatory state. Through searches in PubMed, Redalyc and Google Scholar, 368 articles were identified, 49 references were selected, of which 77.5% were published between 2020 and 2024. The historical periodization includes the initial differentiation of insulin- sensitive and insulin-insensitive diabetic patients in 1936, which laid the foundations for its study. Between 1979 and 1987, the development of the euglycemic-hyperinsulinemic clamp marked an advance in its quantification; from 1988 to 1999, its role in metabolic syndrome was consolidated, and since 2000, research has highlighted the influence of the intestinal microbiota on insulin resistance and its link to inflammation.

Keywords : Insulin Resistance, Low-Grade Systemic Inflammatory State, Metabolic Syndrome.

Video Explanation for Published paper

Never miss an update from Papermashup

Get notified about the latest tutorials and downloads.

Subscribe by Email

Get alerts directly into your inbox after each post and stay updated.
Subscribe
OR

Subscribe by RSS

Add our RSS to your feedreader to get regular updates from us.
Subscribe